Needham Sticks to Its Hold Rating for Tricida (TCDA)

In a report released today, Serge Belanger from Needham maintained a Hold rating on Tricida (TCDAResearch Report). The company’s shares closed yesterday at $0.27.

According to TipRanks, Belanger is an analyst with an average return of -4.8% and a 40.40% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Revance Therapeutics, and KalVista Pharmaceuticals.

The analyst consensus on Tricida is currently a Moderate Sell rating.

See today’s best-performing stocks on TipRanks >>

Based on Tricida’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $28.54 million. In comparison, last year the company had a GAAP net loss of $33.55 million

Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TCDA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tricida, Inc. is a pharmaceutical company, which focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker in 2013 and is headquartered in South San Francisco, CA.

Read More on TCDA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More